| Autor: |
Kelly, Caleb J, Alexeev, Erica E, Farb, Linda, Vickery, Thad W, Zheng, Leon, Eric L, Campbell, Kitzenberg, David A, Battista, Kayla D, Kominsky, Douglas J, Robertson, Charles E, Frank, Daniel N, Stabler, Sally P, Colgan, Sean P |
| Zdroj: |
Gut Microbes; November 2019, Vol. 10 Issue: 6 p654-662, 9p |
| Abstrakt: |
ABSTRACTVitamin B12is a critical nutrient for humans as well as microbes. Due to saturable uptake, high dose oral B12supplements are largely unabsorbed and reach the distal gut where they are available to interact with the microbiota. The aim of this study was to determine if oral B12supplementation in mice alters 1) the concentration of B12and related corrinoids in the distal gut, 2) the fecal microbiome, 3) short chain fatty acids (SCFA), and 4) susceptibility to experimental colitis. C57BL/6 mice (up to 24 animals/group) were supplemented with oral 3.94 µg/ml cyanocobalamin (B12), a dose selected to approximate a single 5 mg supplement for a human. Active vitamin B12(cobalamin), and four B12-analogues ([ADE]CN-Cba, [2Me-ADE]CN-Cba, [2MeS-ADE]CN-Cba, CN-Cbi) were analyzed in cecal and fecal contents using liquid chromatography/mass spectrometry (LC/MS), in parallel with evaluation of fecal microbiota, cecal SCFA, and susceptibility to dextran sodium sulfate (DSS) colitis. At baseline, active B12was a minor constituent of overall cecal (0.86%) and fecal (0.44%) corrinoid. Oral B12supplementation increased active B12at distal sites by >130-fold (cecal B12increased from 0.08 to 10.60 ng/mg, fecal B12increased from 0.06 to 7.81 ng/ml) and reduced microbe-derived fecal corrinoid analogues ([ADE]CN-Cba, [2Me-ADE]CN-Cba, [2MeS-ADE]CN-Cba). Oral B12had no effect on cecal SCFA. Microbial diversity was unaffected by this intervention, however a selective decrease in Bacteroideswas observed with B12treatment. Lastly, no difference in markers of DSS-induced colitis were detected with B12treatment. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
